Financials
Financial year 2025
Revenue
€ 79.9 million
▲ 8% vs 2024
Profit
Healthy€ 7.7 million
▼ 12% vs 2024
Debts
Low€ 34.6 million
▼ 13% vs 2024
CellCarta from Antwerpen, company number BE0474654355, closed financial year 2025 with a result of € 7.7 million after tax. For that financial year CellCarta recorded revenue of € 79.9 million and equity of € 25.9 million. Compared with financial year 2024, the result moved from € 8.8 million to € 7.7 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 9, 2026.
What happened at CellCarta?
What happened at CellCarta in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Elliot Miller stepped down as director. NBB
- Hendriks Consulting Company BV stepped down as director. NBB
- Joshua Schultz stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 7.7 million (▼ 12% vs 2024). Source: NBB ↗
- Maurice Tenney III stepped down as director. NBB
- Kockx - Consulting BV stepped down as director. NBB
- New establishment in Antwerpen. KBO
- Kockx - Consulting BV became a director. NBB
In short
From € 7.7 million profit in 2021 to € 7.7 million profit in 2025.
Paid € 7.5 million in corporate taxes since 2021.
Best year ever: 2024, with € 8.8 million profit.
Paid out € 4.8 million in dividends to the owners in total.
A new publication or filing at CellCarta? We notify you, reason included.
Follow CellCartaNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Histogenex Holding NV (83.3%) and Cellcarta NV (16.7%). It owns 100% of CellCarta China Ltd and 18.5% of PATHOMATION itself.
Directors
According to the 2025 annual accounts
since 2023 · until 2026
since 2025 · until 2031
since 2019 · until 2025
Managing director · represented by Mark Kockx
Also active at: BATYO, PATHOMATION, HistoGeneX Holding +1 more
since 2025 · until 2026
since 2022 · until 2025
since 2025 · until 2030
Hendriks Consulting Company BV
Managing director · represented by Dirk Hendriks
Also active at: HistoGeneX Holding, Arsenal IO Belgium
since 2025 · until 2031
Shareholders
83.3%
16.7%
Participations
CellCarta China Ltd
100%
18.5%
Establishments
Establishment units
Physical locations of this company
Sint-Bavostraat 78
2610 Antwerpen
Sneeuwbeslaan 20
2610 Antwerpen
Active since 1 December 2025
Neerlandweg 11
2610 Antwerpen
Active since 1 January 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
Details
- Company number
- 0474.654.355
- VAT number
- BE 0474.654.355
- Registered office
- Sint-Bavostraat 78, 2610 Antwerpen
- Names & denominations
- CellCarta
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 April 2001
- Peppol
- Active · Active since 14 Oct 2025
- Contact
- info@histogenex.com +32 3 502 05 00
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Medische laboratoria
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied